|Bid||4.7600 x 800|
|Ask||4.7700 x 1400|
|Day's Range||4.5760 - 4.9700|
|52 Week Range||1.4000 - 6.0700|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep. 30, 2020 - Oct. 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
EMERYVILLE, Calif., June 22, 2020 /CNW/ -- Amyris, Inc. (Nasdaq:AMRS - News), a leading biotechnology company in the Clean Health and Beauty markets and a top supplier of sustainable and natural ingredients, and AB Mauri North America, a global supplier of yeast and baking ingredients, jointly announced an exclusive multi-year agreement for the sale and purchase of Amyris' Purecane™ RebM zero-calorie sweetener for baking applications. This partnership is expected to transform the industrial baking sector in the US, Mexico and Canada markets by enabling AB Mauri's customers to produce reduced sugar baked goods with no loss of flavor, texture or product appeal.
Investors enjoyed modest gains on Wall Street to start the new week, with the markets reacting favorably to a lack of news on the geopolitical front. The Dow Jones Industrial Average (DJINDICES: ^DJI), S&P 500 (SNPINDEX: ^GSPC), and Nasdaq Composite (NASDAQINDEX: ^IXIC) were all up in the neighborhood of half a percent. Amyris (NASDAQ: AMRS) and Coty (NYSE: COTY) aren't household names, but they made their shareholders a lot happier today.
Shares of Amyris (NASDAQ: AMRS) soared as much as 20.9% today after an article on Seeking Alpha suggested the synthetic biology company could be the next Tesla. On the one hand, what investor wouldn't want to own the next Tesla? Shares of the electric vehicle manufacturer and energy pioneer have jumped 3,570% since the initial public offering (IPO).
Investors are less than two years removed from a significant accounting discrepancy. A closer look at SEC filings reveals another potential cause for concern.
Investors were pleased by relatively positive operating results in the first quarter of 2020. Can the synthetic biology company turn those results into a durable trend?
NEW YORK, NY / ACCESSWIRE / April 21, 2020 / Levi & Korsinsky announces it has commenced an investigation of Amyris, Inc. (NASDAQ:AMRS) concerning possible breaches of fiduciary duty. To obtain additional ...
John Melo has been the CEO of Amyris, Inc. (NASDAQ:AMRS) since 2007. First, this article will compare CEO compensation...
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Amyris, Inc. (NASDAQ:AMRS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:30 PM Eastern ...
Those following along with Amyris, Inc. (NASDAQ:AMRS) will no doubt be intrigued by the recent purchase of shares by...
If you own shares in Amyris, Inc. (NASDAQ:AMRS) then it's worth thinking about how it contributes to the volatility of...
EMERYVILLE, Calif. , Dec. 27, 2019 /CNW/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported that it has successfully shipped the first cannabinoid to its partner, LAVVAN. Amyris is also well on its way to the shipment of a second cannabinoid in the first half of 2020. The company's technology allows Amyris to scale ingredients that are rarer within the cannabis plant, and difficult and extremely expensive to extract in quantity.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Pomerantz LLP is investigating claims on behalf of investors of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ: AMRS). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. On this news, Amyris’s stock price fell $1.76 per share, or 29.83%, to close at $4.14 per share on November 14, 2018.
Beyond Meat is just the beginning of a new emerging cohort of innovative companies. These innovators are changing how we feed the planet without consuming more of its resources.
NEW YORK, NY / ACCESSWIRE / August 27, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amyris, Inc.(“Amyris” or “the Company”) (AMRS). Investors who purchased Amyris stock are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/amrs. The investigation concerns whether Amyris and certain of its officers and/or directors have violated federal securities laws.